A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin (the DUNE trial)
Latest Information Update: 28 Feb 2023
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoid tumour; Gastrointestinal stromal tumours; Lung cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms DUNE
- 22 Feb 2023 Status changed from active, no longer recruiting to completed.
- 02 Aug 2022 Planned End Date changed from 1 Apr 2022 to 1 Dec 2022.
- 02 Aug 2022 Status changed from recruiting to active, no longer recruiting.